Dianthus Therapeutics (NASDAQ:DNTH) Shares Cross Below 50-Day Moving Average – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) shares passed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $87.64 and traded as low as $85.43. Dianthus Therapeutics shares last traded at $86.98, with a volume of 562,351 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on DNTH shares. JPMorgan Chase & Co. assumed coverage on Dianthus Therapeutics in a research report on Friday, September 11th. They set an “overweight” rating and a $135.00 price target on the stock. Citigroup initiated coverage on Dianthus Therapeutics in a report on Friday, September 4th. They issued a “buy” rating and a $156.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Wedbush boosted their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $134.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, November 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Buy” and a consensus target price of $128.77.

Read Our Latest Research Report on DNTH

Dianthus Therapeutics Stock Performance

The company has a market capitalization of $4.90 billion, a P/E ratio of -21.80 and a beta of 1.47. The business has a 50 day moving average of $87.64 and a 200-day moving average of $86.93.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $0.46 million. As a group, equities analysts forecast that Dianthus Therapeutics, Inc. will post -3.55 EPS for the current fiscal year.

Insider Activity

In related news, CAO Edward Carr sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total transaction of $2,027,600.00. Following the completion of the transaction, the chief accounting officer owned 20,000 shares of the company’s stock, valued at approximately $2,027,600. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Simrat Randhawa sold 23,124 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at $425,640. This trade represents a 85.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 167,166 shares of company stock worth $15,716,765. 3.02% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. ABS Investment Management LLC purchased a new stake in shares of Dianthus Therapeutics in the second quarter worth $194,960,000. EFG International AG purchased a new position in Dianthus Therapeutics during the second quarter worth about $49,000. GAMMA Investing LLC grew its position in Dianthus Therapeutics by 83.6% during the third quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after buying an additional 254 shares in the last quarter. Allworth Financial LP grew its position in Dianthus Therapeutics by 214.1% during the third quarter. Allworth Financial LP now owns 603 shares of the company’s stock worth $53,000 after buying an additional 411 shares in the last quarter. Finally, Fifth Third Bancorp increased its stake in Dianthus Therapeutics by 23.6% in the 3rd quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock worth $60,000 after acquiring an additional 129 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.

Further Reading

Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.